Journal ArticleDOI
Development trends for human monoclonal antibody therapeutics
Reads0
Chats0
TLDR
Data is analysed on 147 human mAbs that have entered clinical study to highlight trends in their development and approval, which may help inform future studies of this class of therapeutic agents.Abstract:
Fully human monoclonal antibodies (mAbs), which have the potential to be less immunogenic than earlier humanized and chimeric mAbs, are the most rapidly growing class of mAbs in clinical development. Here, Reichert and colleagues highlight trends in the development of human mAbs, seven of which have so far gained regulatory approval.read more
Citations
More filters
Journal ArticleDOI
Antibody therapy of cancer
TL;DR: This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.
Journal ArticleDOI
Nanomedicine(s) under the Microscope
Ruth Duncan,Rogério Gaspar +1 more
TL;DR: Both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future are reviewed.
Journal ArticleDOI
Contribution of Organofluorine Compounds to Pharmaceuticals.
TL;DR: This mini-review analyzes the prevalence of fluoro-pharmaceuticals in the market and categorizes them into several groups based on the chemotype of thefluoro-functional groups, their therapeutic purpose, and the presence of heterocycles and/or chirality to highlight the structural motifs, patterns, and promising trends in fluorine-based drug design.
Journal ArticleDOI
Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Paul Carter,Greg A. Lazar +1 more
TL;DR: This Review focuses on emerging and novel mechanisms of action of antibodies and innovative targeting strategies that could extend their therapeutic applications, including antibody–drug conjugates, bispecific antibodies and antibody engineering to facilitate more effective delivery.
Journal ArticleDOI
Dual targeting strategies with bispecific antibodies
TL;DR: This review discusses the various dual targeting strategies for which bispecific antibodies have been developed and provides an overview of the established bispespecific antibody formats.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Phage antibodies: filamentous phage displaying antibody variable domains
TL;DR: It is shown that complete antibody V domains can be displayed on the surface of fd bacteriophage, that the phage bind specifically to antigen and that rare phage can be isolated after affinity chromatography.
A Randomized Double-blind Placebo-controlled Trial
TL;DR: The purpose of the present investigation was to evaluate the safety and effectiveness of the antiviral drug amantadine for the treatment of hepatitis C in those who had either previously failed interferon therapy or were not candidates for interferons.
Journal ArticleDOI
Making antibody fragments using phage display libraries
TL;DR: Using a random combinatorial library of the rearranged heavy and kappa light chains from mice immune to the hapten 2-phenyloxazol-5-one (phOx), diverse libraries of antibody fragments are displayed on the surface of fd phage and elicited many more pairings with strong binding activities.
Journal ArticleDOI
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Filip Baert,Maja Noman,Severine Vermeire,Gert Van Assche,Geert D' Haens,An Carbonez,Paul Rutgeerts +6 more
TL;DR: The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment, and concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.
Related Papers (5)
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more